After two volatile years, FDA approvals in 2024 settled closer to their 10-year average. Will nominated commissioner Marty Makary shake things up, or maintain a steady ship?
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
209,00 € per year
only 17,42 € per issue
Buy this article
Purchase on SpringerLink
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
References Senior, M. Nat. Biotechnol. 42, 355–361 (2024).
Article
CAS
PubMed
Google Scholar
Senior, M. Nat. Biotechnol. 41, 174–182 (2023).
Article
CAS
PubMed
PubMed Central
Google Scholar
Yiannopoulou, K. G., Anastasiou, A. I., Zachariou, V. & Pelidou, S. H. Biomedicines 7, 97 (2019).
Article
CAS
PubMed
PubMed Central
Google Scholar
Schmidt, M. E. et al. Neuropsychopharmacology 49, 1437–1447 (2024).
Article
CAS
PubMed
PubMed Central
Google Scholar
Shiga, T. Eur. Heart J. Suppl. 24, D11–D21 (2022). (Suppl. D).
Article
CAS
PubMed
PubMed Central
Google Scholar
Senior, M. Nat. Biotechnol. 42, 362–366 (2024).
Article
CAS
PubMed
Google Scholar
Senior, M. Nat. Biotechnol. 42, 1331–1338 (2024).
Article
CAS
PubMed
Google Scholar
Senior, M. Nat. Biotechnol. https://doi.org/10.1038/s41587-024-02506-7 (2024).
Article
PubMed
Google Scholar
Download references
Author information Authors and Affiliations London, UK
Melanie Senior
Rights and permissions About this article
Cite this article Senior, M. Fresh from the biotech pipeline: FDA approvals settle in 2024, but what next?.
Nat Biotechnol (2025). https://doi.org/10.1038/s41587-025-02555-6
Download citation
Published: 20 January 2025
DOI : https://doi.org/10.1038/s41587-025-02555-6
Leave a Reply